Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 47 of 47 results for doxorubicin

  1. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    6 March 2024
    View recommendations

    Sections for TA954

  2. Research recommendations

    undertaken to compare the efficacy of trabectedin plus pegylated liposomal doxorubicin hydrochloride (PLDH) with platinum-based...